RxDoctor Payments Data

Insoo Om, PA

Physician Assistant · Bronx, NYNPI 1538364989

Payments from drug & device makers

$11,701in general payments, 2019–2025

Across 520 payments — averaging $22.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Johnson & Johnson$1K
  • UCB, Inc.$1K
  • Dermavant Sciences, Inc.$1K
  • Sun Pharmaceutical Industries Inc.$1K
  • Arcutis Biotherapeutics, Inc.$845
  • plus $4K from 17 others

What the payments were for

  • Food & beverage$11,19196%
  • Education$5094%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,701 in reported general payments places this provider in the 95th percentile of 11,358 physician assistant providers in New York.

See all physician assistant providers in New York

Medicare billing

Part B allowed, 2024
$34,713
Medicare patients
38
Services billed
1,002

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OpzeluraRuxolitinib Phosphate63$133,379
Dupixent PenDupilumab34$123,370
ErtaczoSertaconazole Nitrate132$117,323
JubliaEfinaconazole35$56,627
VtamaTapinarof37$49,339
Clobetasol Propionate408$36,471
Ketoconazole603$34,794
Doxepin Hcl134$25,952
ZoryveRoflumilast25$20,824
Hydrocortisone193$17,117
Amcinonide11$13,814
Minoxidil265$13,318
Metronidazole139$12,931
Fluocinonide91$7,312
Clindamycin Phosphate88$7,138

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Incyte CorporationOpzelura$611$133,37963 claims
Ortho Dermatologics, A Division Of Bausch Health US, LLCJublia$496$56,62735 claims
Dermavant Sciences, Inc.Vtama$1,319$49,33937 claims
Arcutis Biotherapeutics, Inc.Zoryve$845$20,82425 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 11,358 physician assistant providers in New York.

Other physician assistant in Bronx

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →